Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Sess

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Sess#Alnylam #Presents #Data #HELIOSB #Phase #Study #Vutrisiran #Patients #ATTR #Amyloidosis #Cardiomyopathy #ATTRCM #American #College #Cardiology039s #Annual #Scientific #Sess